| News

ten23 health settles in Basel

02.09.2021

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health. As a partner, it hopes to support leading global biotech and pharma clients with the development, manufacture, and testing of injectable biopharmaceuticals.

Ten23 health has announced that it has commenced operations in Basel. Its company headquarters are located on the Rosental Mitte campus. A new working environment for 150 full-time positions is being offered over 4,000 square meters of laboratory and office space in the building that was formerly home to Elanco.

The company hopes to use its scientific competence and its “globally recognized” expertise in industry and regulations to support clients from the global biotech and pharmaceutical industries with the development, manufacture, and testing of injectable biopharmaceuticals. It is “solidly financed” through the commitment of the UK-based associated company 3i Group.

Ten23 health states that it is led by a world-class leadership team and is able to demonstrate “outstanding expertise” in the biopharmaceutical industry, pharmaceutical and analytical sciences, development, and regulatory requirements. The team headed up by CEO Prof. Dr. Hanns-Christian Mahler has “a proven track record in the field of pharmaceutical product design and development” as well as an “extensive global pharma network”.

The CEO adds: “Our comprehensive offering will allow our clients to focus on the medicine and the patient, whilst leveraging our pharmaceutical expertise and knowledge to plan and de-risk product development.” The aim is to enable rapid, high-quality, successful commercialization.

Richard Relyea, a Partner at 3i and a Member of the Board of Directors of ten23 health, emphasizes the holistic approach of ten23 health, saying: “We will deliver services in an engrained, fair and sustainable manner.” By investing in ten23 health, 3i intends to support “the establishment of a uniquely differentiated partner to leading global biotech and pharmaceutical customers”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Roche tests able to detect Omicron
Basel Area Business & Innovation, Innovation, Invest

Roche tests able to detect Omicron

The Roche subsidiary TIB Molbiol has developed new coronavirus testing kits that can also detect the new Omicron variant of...

Read More
Hemex banks 7.1 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Hemex banks 7.1 million Swiss francs

Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company...

Read More
EsoCap impresses investors
Basel Area Business & Innovation, Innovation, Invest

EsoCap impresses investors

EsoCap, a biotech company based in Basel, has concluded a successful funding round. The funds from new and existing investors...

Read More
Plug and Play settles in the Basel Area
Basel Area Business & Innovation, Innovation, Invest

Plug and Play settles in the Basel Area

Plug and Play is coming to the canton of Basel-Landschaft. The first founding partner of the innovation promoter from Silicon...

Read More
Bachem builds its largest production building
Basel Area Business & Innovation, Innovation, Invest

Bachem builds its largest production building

Bachem has laid the foundation stone for its largest production building to date. The company specializing in the manufacture of...

Read More
Bottneuro advancing personalized Alzheimer’s therapy
Basel Area Business & Innovation, Innovation, Invest

Bottneuro advancing personalized Alzheimer’s therapy

Basel-based startup Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of...

Read More
1 2 3 50

Do you have a question? We'd like to hear from you.